^
Association details:
| Biomarker: | RAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-Line Durvalumab and Tremelimumab With Chemotherapy for RAS-Mutated Metastatic Colorectal Cancer
Published date:
09/04/2023
Excerpt:
The single-arm, phase 1b/2 MEDITREME trial evaluated the safety and efficacy of durvalumab plus tremelimumab combined with mFOLFOX6 chemotherapy in first line, in 57 patients with RAS-mutant unresectable metastatic CRC....The phase 2 primary objective of efficacy in terms of 3-month progression-free survival (PFS) in patients with MSS tumors was met, with 3-month PFS of 90.7% (95% confidence interval (CI): 79.2-96%). For secondary objectives, response rate was 64.5%; median PFS was 8.2 months (95% CI: 5.9-8.6)...The combination of durvalumab-tremelimumab with mFOLFOX6 was tolerable with promising clinical activity in MSS mCRC.
Secondary therapy:
mFOLFOX6
Source:
Title:
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
Published date:
08/10/2023
Excerpt:
The single-arm, phase 1b/2 MEDITREME trial evaluated the safety and efficacy of durvalumab plus tremelimumab combined with mFOLFOX6 chemotherapy in first line, in 57 patients with RAS-mutant unresectable metastatic CRC….The phase 2 primary objective of efficacy in terms of 3-month progression-free survival (PFS) in patients with MSS tumors was met, with 3-month PFS of 90.7% (95% confidence interval (CI): 79.2–96%). For secondary objectives, response rate was 64.5%; median PFS was 8.2 months (95% CI: 5.9–8.6)...
Secondary therapy:
mFOLFOX6
DOI:
https://doi.org/10.1038/s41591-023-02497-z
Trial ID:
